Bangalore-based biotech firm Biocon has protested against the drug price regulator National Pharma Pricing Authority's (NPPA) insulin price fixation methodology, which it says discriminates against domestically produced insulin.
“We have been requesting the government to provide a level playing field for all players in the market, domestic as well as MNCs, and do away with a dual pricing mechanism for insulins," said Kiran Mazumdar Shaw, CMD, Biocon on Tuesday.
We have suggested that government have a common ceiling price for insulin products. "The latest ruling with two ceiling prices, one for domestic product and other for imported ones, defies the purpose and fails to address the basic issue, " she said.
A latest NPPA price revision allows imported human insulin injection-40 IU of 10 ml vial to be marketed at a ceiling price of R160 (MRP R167) while a comparable domestic insulin can only be marketed at a ceiling price of R135 (MRP R140). For the imported insulin injection of 100 IU of 10 ml vial, NPPA has fixed a ceiling price of R285 (MRP R296) while a similar domestic product can only be sold at R265 (MRP R275). The ceiling price of domestically produced human insulin 100 IU, 3 ml cartridge has been set at R145 while an imported version can be sold for R200 on a like-to-like basis.